- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07752732
Non-Interventional Study on the Prevalence of Cardiac Amyloidosis in Patients With Higher-Grade Aortic Valve Stenosis - Evaluation Using Echocardiography, Computed Tomography, Tc99-SPECT/CT and Cardiac Magnetic Resonance Imaging (CMR) (NIS-TAVI-AMY)
Degenerative aortic stenosis (AS) is frequently accompanied by left ventricular hypertrophy and diastolic dysfunction, features that overlap with transthyretin (ATTR) cardiac amyloidosis. Because concomitant cardiac amyloidosis may adversely affect outcomes after transcatheter aortic valve implantation (TAVI), its early detection is clinically important.
This prospective observational study aims to evaluate multimodal imaging biomarkers for the detection and characterization of cardiac amyloidosis in patients with severe AS undergoing TAVI evaluation. Clinically indicated technetium-99m phosphonate SPECT/CT and CT will be used to assess the presence and extent of cardiac amyloidosis, including quantitative measures of myocardial tracer uptake and extracellular volume. In patients with abnormal findings, cardiac magnetic resonance imaging (CMR) will be performed as an additional non-invasive imaging modality according to institutional clinical practice.
The study will determine the prevalence of cardiac amyloidosis in this population and investigate the diagnostic and prognostic value of imaging-derived quantitative parameters. Standardized clinical follow-up at 6, 12, and 24 months will assess associations between imaging biomarkers and clinical outcomes. The study is observational and does not alter routine clinical management or diagnostic pathways.
Visão geral do estudo
Status
Descrição detalhada
Degenerative aortic valve stenosis (AS) is currently the most common heart valve disease in western countries. It is defined as aortic valve opening area <1.0cm² and/or an average gradient of 40mmHg. Elderly patients with higher-grade AS are primarily treated interventionally by means of transcatheter aortic valve implantation (TAVI). The outcome here does not seem to be any worse compared to conventional/cardiac aortic valve replacement. A hallmark of higher grade AS is left ventricular hypertrophy. In addition, there is often a restrictive filling pattern, which can be demonstrated in echocardiography. These characteristics are also found in cardiac amyloidosis of the TTR type (transthyretin type). Amyloid was found in over 70% of surgically removed heart valves in patients who received an aortic valve replacement. The detection of amyloid is of clinical importance for the patient, since there are different therapeutic approaches depending on the respective amyloid form. Endomyocardial biopsy (EMB) is currently the gold standard for the detection of cardiac amyloidosis in many places. However, it is an invasive procedure with associated risks and limitations (e.g. sampling error). Cardiac amyloidosis can be recognized non-invasively by the calcium-associated storage of technetium 99m (Tc99m)-labelled phosphonates, as is traditionally used in skeletal scintigraphy. According to the previous data, Tc99m phosphonate scintigraphy using SPECT/CT has a high specificity for the detection of TTR amyloidosis. If a SPECT/CT is available, this non-invasive diagnostic procedure is preferred to EMB.
The previous data indicate a correlation between the prognosis and the phosphonate storage in the myocardium. Using the Perugini score, the tracer uptake is only classified as a discrete size in a rough grid. A quantification of myocardial radiopharmaceutical intake could provide quantitative parameters that not only better reflect the severity of cardiac amyloidosis, but could also serve as a prognostic parameter. Such a quantification could take place through hybrid imaging using SPECT/CT, in which the anatomical information from computer tomography (CT) is combined with the functional information from single photon emission tomography (SPECT). This quantification takes place in a post-processing of the acquired data sets.
In addition to Tc99-SPECT/CT, cardiac MRI (CMR) with its excellent tissue characterization can also display inflammatory and fibrotic changes in the heart muscle, as can occur in amyloidosis as part of protein deposition. In addition to the established late gadolinium enhancement (LGE) technique, which can primarily map focal fibrotic processes with high accuracy, current CMR techniques for tissue characterization (T1/T2 mapping) can also be used to quantify diffuse myocardial changes, and distinguish fibrotic from inflammatory changes of the heart muscle by T1 or T2 weighting. If the Tc99-SPECT/CT findings are noticeable, a subsequent CMR is carried out for verification at the UKT as standard. This is the case in approximately 10% of patients.
If early detection of cardiac amyloidosis is assured, the clinical course of the patient could possibly be positively influenced by timely adequate therapy.
The aim of this study is to first determine the prevalence of cardiac amyloidosis using SPECT/CT and, if available, to quantify it. In patients with conspicuous SPECT/CT, the multimodal CMR is then (still) more likely to make possible cardiac amyloidosis as a second non-invasive method. The standardized follow-up after 6 or 12/24 months is planned to check the parameters determined by imaging technology (Tc99-SPECT/CT (or CMR)) for their prognostic relevance.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Patrick Krumm, Prof. Dr. med.
- Número de telefone: +49 7071 29 68119
- E-mail: patrick.krumm@med.uni-tuebingen.de
Estude backup de contato
- Nome: Studienzentrum Bildgebung Radiology
- Número de telefone: +49 7071 29 85251
- E-mail: studienzentrum-radiologie@med.uni-tuebingen.de
Locais de estudo
-
-
-
Tübingen, Alemanha, 72076
- Recrutamento
- University Hospital of Tuebingen
-
Contato:
- Jan M. Brendel, PD Dr. med.
- Número de telefone: +49 7071 29 68528
- E-mail: jan.brendel@med.uni-tuebingen.de
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Patients with severe aortic valve stenosis (valve opening area <1 cm², pmean >40 mmHg, Vmax >4 m/sec)
- Suspected cardiac amyloidosis
- Performance of one or more of the following imaging examinations due to (justifiable) clinical indication: echocardiography, photon-counting computed tomography (CT), Tc99-SPECT/CT, cardiac MRI
- Age ≥18 years
- Written consent of the patient for prospective data collection regarding Tc99-SPECT/CT, CT, and, if applicable, CMR and follow-up
Exclusion Criteria:
• patients unable to give consent
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Patients with higher grade aortic stenosis
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of Participants Diagnosed with Cardiac Amyloidosis
Prazo: At baseline
|
Presence of cardiac amyloidosis as determined by the study imaging protocol and diagnostic criteria.
The prevalence will be reported as the proportion of participants diagnosed with cardiac amyloidosis among patients with severe aortic valve stenosis.
|
At baseline
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants Experiencing Adverse Cardiac Events
Prazo: Up to 2 years after enrollment
|
Occurrence of major adverse cardiovascular events during follow-up.
The prognostic value of the imaging examinations will be assessed.
|
Up to 2 years after enrollment
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Patrick Krumm, Prof. Dr. med., University Hospital of Tuebingen
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doença da Valva Aórtica
- Doenças do Sistema Nervoso
- Doenças Vasculares
- Doenças cardiovasculares
- Condições Patológicas, Anatômicas
- Doenças cardíacas
- Doenças Neuromusculares
- Metabolismo, Erros Inatos
- Doenças Genéticas, Congênitas
- Doenças Metabólicas
- Doenças do Sistema Nervoso Periférico
- Doenças Neurodegenerativas
- Doenças das válvulas cardíacas
- Obstrução do Fluxo Ventricular
- Distúrbios Heredodegenerativos, Sistema Nervoso
- Deficiências de Proteostase
- Doença cardíaca
- Isquemia do miocárdio
- Neuropatias Amilóides
- Amiloidose Familiar
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Condições Patológicas, Sinais e Sintomas
- Doenças Nutricionais e Metabólicas
- Estenose da Válvula Aórtica
- Constrição Patológica
- Estenose Coronária
- Amiloidose
- Neuropatias Amilóides Familiares
Outros números de identificação do estudo
- 766/2019BO2
- DRKS00020481 (Outro identificador: DRKS, German Clinical Trials Register)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .